Quote
Entrada isn’t the only start-up working on CPPs. Earlier this year, Feldan Therapeutics raised $13.8 million in its series A financing to develop a CPP technology for intracellular biologics delivery, including delivery of the Cas9 protein and guide RNA complex that compose the CRISPR gene editing system. Entrada doesn’t have plans to use CPPs for CRISPR delivery at this time, Sethuraman says, but the company is open to looking at all opportunities.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.30 |
Change
-0.025(1.89%) |
Mkt cap ! $755.3M | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.32 | $1.30 | $478.1K | 365.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |